Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA.
STATinMED Research, Plano, TX, USA.
Inflamm Bowel Dis. 2022 Jun 3;28(6):870-877. doi: 10.1093/ibd/izab198.
Perianal fistula (PAF), a complication of Crohn's disease (CD), is associated with substantial economic costs and poor prognosis. We determined prevalence of PAF CD in the United States and compared costs and health care resource utilization (HRU) of PAF CD patients with matched non-PAF CD patients.
This was a retrospective cohort study of claims data from the IBM MarketScan Commercial Database from October 1, 2015, to September 30, 2018. Eligible patients were aged 18 to 89 years with ≥2 CD diagnoses. Patients with PAF CD had ≥1 PAF diagnosis or procedure code and were matched with non-PAF CD patients. Cumulative prevalence of PAF CD in the US population was calculated across total patients in MarketScan. All-cause and gastrointestinal (GI)-related costs and HRU were compared between groups using a generalized linear model (GLM).
Cumulative 3-year prevalence of PAF was 7.70% of patients with CD (N = 81,862) and 0.01% of the US population. Among PAF CD (n = 1218) and matched non-PAF CD (n = 4095) patients, most all-cause costs and HRU were GI-related. Mean total all-cause and GI-related health care costs per patient and per year for PAF CD were $85,233 and $71,612, respectively, vs $40,526 and $29,458 for non-PAF CD (P < .0001). Among PAF CD vs non-PAF CD patients, GLM-adjusted proportions of patients with GI-related inpatient, outpatient, or pharmacy visits, mean GI-related inpatient length of stay, and mean GI-related surgeries were higher (P < .0001 for all comparisons).
Costs and HRU are significantly higher for patients with PAF CD vs non-PAF CD patients, highlighting the economic burden of the disease.
肛周瘘(PAF)是克罗恩病(CD)的一种并发症,与巨大的经济成本和不良预后相关。我们确定了美国 PAF CD 的患病率,并比较了 PAF CD 患者与匹配的非 PAF CD 患者的成本和医疗资源利用(HRU)。
这是一项回顾性队列研究,使用 IBM MarketScan 商业数据库从 2015 年 10 月 1 日至 2018 年 9 月 30 日的数据。合格的患者年龄在 18 至 89 岁之间,至少有 2 次 CD 诊断。PAF CD 患者有≥1 次 PAF 诊断或手术代码,并与非 PAF CD 患者匹配。通过市场扫描中所有患者的累积流行率来计算美国人群中 PAF CD 的流行率。使用广义线性模型(GLM)比较两组之间的全因和胃肠道(GI)相关成本和 HRU。
3 年内 PAF 的累积患病率为 CD 患者的 7.70%(N=81862)和美国人口的 0.01%。在 PAF CD(n=1218)和匹配的非 PAF CD(n=4095)患者中,大多数全因和 HRU 与 GI 相关。PAF CD 患者的平均全因和 GI 相关医疗保健费用为每位患者每年 85233 美元和 71612 美元,而非 PAF CD 患者为 40526 美元和 29458 美元(P<0.0001)。与非 PAF CD 患者相比,PAF CD 患者接受 GI 相关住院、门诊或药房就诊的比例、GI 相关住院平均住院时间和 GI 相关手术的平均比例均较高(所有比较的 P<0.0001)。
与非 PAF CD 患者相比,PAF CD 患者的成本和 HRU 明显更高,突出了疾病的经济负担。